338 related articles for article (PubMed ID: 18980540)
1. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2008 Nov; 7(9):1367-94. PubMed ID: 18980540
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
3. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
[TBL] [Abstract][Full Text] [Related]
4. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease.
Hausdorff WP; Dagan R; Beckers F; Schuerman L
Vaccine; 2009 Dec; 27(52):7257-69. PubMed ID: 19833248
[TBL] [Abstract][Full Text] [Related]
5. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.
Davis SM; Deloria-Knoll M; Kassa HT; O'Brien KL
Vaccine; 2013 Dec; 32(1):133-45. PubMed ID: 23684824
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal vaccines.
Ho CF; Lin TY
Chang Gung Med J; 2005 Nov; 28(11):765-72. PubMed ID: 16422182
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
8. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
9. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
Millar EV; Watt JP; Bronsdon MA; Dallas J; Reid R; Santosham M; O'Brien KL
Clin Infect Dis; 2008 Oct; 47(8):989-96. PubMed ID: 18781875
[TBL] [Abstract][Full Text] [Related]
10. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
Fitzwater SP; Chandran A; Santosham M; Johnson HL
Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
[TBL] [Abstract][Full Text] [Related]
11. Prevenar vaccination: review of the global data, 2006.
Center KJ
Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
[TBL] [Abstract][Full Text] [Related]
12. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
[TBL] [Abstract][Full Text] [Related]
16. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
Dagan R
Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
Oosterhuis-Kafeja F; Beutels P; Van Damme P
Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
[TBL] [Abstract][Full Text] [Related]
18. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
Bechini A; Boccalini S; Bonanni P
Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
[TBL] [Abstract][Full Text] [Related]
19. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
Paradiso P
Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657
[TBL] [Abstract][Full Text] [Related]
20. New insights on pneumococcal disease: what we have learned over the past decade.
Dagan R
Vaccine; 2009 Aug; 27 Suppl 3():C3-5. PubMed ID: 19552985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
